A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this exploratory study is to evaluate the safety of rivaroxaban and
uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial
fibrillation (NVAF) who undergo catheter ablation as measured by post-procedure major
bleeding events.